Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody

Catalog # Availability Size / Price Qty
AF-396-NA
AF-396-SP
Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human NRG1‑ beta 1/HRG1‑ beta 1 Antibody.
2 Images
Product Details
Citations (2)
FAQs
Supplemental Products
Reviews

Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody Summary

Species Reactivity
Human
Specificity
Detects human NRG1‑ beta 1/HRG1‑ beta 1 EGF Domain in direct ELISAs and Western blots. In Western blots (reducing conditions), approximately 100% cross‑reactivity with recombinant human HRG-alpha is observed. In direct ELISAs, approximately 5% cross‑reactivity with recombinant human HRG-alpha is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human NRG1‑ beta 1/HRG1‑ beta 1 EGF Domain
Thr176-Lys246
Accession # NP_039250
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human NRG1-beta 1/HRG1-beta 1 EGF Domain (Catalog # 396-HB)
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize NRG1‑ beta 1/HRG1‑ beta 1-induced proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 0.5‑2.0 µg/mL in the presence of 0.75 ng/mL Recombinant Human NRG1‑ beta 1/HRG1‑ beta 1 EGF Domain.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Neutralization Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human NRG1‑ beta 1/HRG1‑ beta 1 Antibody. View Larger

Cell Proliferation Induced by NRG1‑ beta 1/HRG1‑ beta 1 and Neutralization by Human NRG1‑ beta 1/HRG1‑ beta 1 Antibody. Recombinant Human NRG1-beta 1/ HRG1-beta 1 EGF Domain (Catalog # 396-HB) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-beta 1/ HRG1-beta 1 EGF Domain (0.75 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-396-NA). The ND50 is typically 0.5-2.0 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Neuregulin-1 beta 1/NRG1 beta 1

The neuregulin family of structurally related glycoproteins comprises products from four distinct but related genes, Nrg-1, Nrg-2, Nrg-3, and Nrg-4. Through alternative splicing or the use of alternative promoters, Nrg-1 has been shown to encode more than 14 soluble or transmembrane proteins. The extracellular domain of the transmembrane NRG1 isoforms can be proteolytically cleaved to release soluble growth factors. All NRG1 isoforms contain an EGF‑like domain ( alpha - or beta -splice variant that differ in their C-terminal region) that is required for their direct binding to the ErbB3 or ErbB4 receptor tyrosine kinases. The ErbB3 or ErbB4 subsequently recruits and heterodimerizes with ErbB2, resulting in tyrosine phosphorylation and NRG1 signaling. NRG1 isoforms can be classified into three major subtypes. Type I (Neu Differentiation Factor, NDF; Heregulin, HRG; Acetylcholine Receptor Inducing Activity, ARIA) and type II (Glial Growth Factor, GGF) NRG1s have an immunoglobulin (Ig)-like domain N-terminal to the EGF‑like domain. Type I NRG1s differ from type II NRG1s by having a glycosylation-rich domain between the Ig‑like and the EGF‑like domains. Type III NRG1s (Sensory and Motor neuron-Derived Factor) lacks the Ig‑like domain but has a cysteine rich domain (CRD) instead. NRG1 isoforms show distinct spatial and temporal expression patterns. These proteins play important roles during development of both the nervous system and the heart. They have been shown to regulate the selective expression of neurotransmitter receptors in neurons and at the neuromuscular junction, and promote the differentiation and development of Schwann cells from neural crest stem cells. NRG1s have also been shown to be involved in the establishment of the oligodendroglial lineage.

References
  1. Buonanno, A., and Fischbach, G.D. (2001) Curr. Opin. Neurobiol. 11:287.
  2. Adlkofer, K. and Lai, C. (2000) Glia 29:104.
  3. Garratt, A.N. et al. (2000) BioEssays 22:987.
Entrez Gene IDs
3084 (Human); 211323 (Mouse); 112400 (Rat)
Alternate Names
ARIA; GGF; GGF2; HGL; HRG; HRG1; HRGA; MST131; MSTP131; NDF; neuregulin 1; Neuregulin1 beta 1; Neuregulin-1 beta 1; NRG1-IT2; SMDF

Product Datasheets

You must select a language.

x

Citations for Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

  1. CAN017, a novel anti-HER3 antibody, exerted great potency in mouse avatars of esophageal squamous cell carcinoma with NRG1 as a biomarker
    Authors: H Liao, C Zhang, Z Chen, Y Gao, Z Li, L Wang, Y Li, L Shen, J Gao
    American journal of cancer research, 2021;11(4):1697-1708.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  2. Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis.
    Authors: Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T
    Circ. Res., 2009;105(5):500-10.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody

There are currently no reviews for this product. Be the first to review Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody and earn rewards!

Have you used Human NRG1-beta 1/HRG1-beta 1 EGF Domain Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review